-

Thermo Fisher Scientific Enables Semiconductor Manufacturers to See the Unseen with Helios MX1 PFIB-SEM

New solution uses automated 3D metrology to increase productivity in fabrication environments

WALTHAM, Mass.--(BUSINESS WIRE)--From smartphones to autonomous cars to AI supercomputers, nearly every electronic innovation we use today depends on complicated structures at the atomic scale within silicon chips. As these chips increase in processing power and decrease in size, even the smallest fault can cause massive delays.

To help chipmakers keep pace and minimize delays, Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Helios™ MX1 Plasma Focused Ion Beam (PFIB) Scanning Electron Microscope (SEM). This system enables chip manufacturers to visualize and analyze buried semiconductor structures directly within fabrication (fab) environments.

Helios MX1 uses automated 3D reconstruction and metrology to significantly enhance the analysis of semiconductor logic, memory and advanced packaging devices. This fully automated wafer analysis system is uniquely designed to increase productivity in the fab by accelerating time-to-data — the speed at which engineers can see and understand what’s happening deep within a semiconductor.

Seeing the unseen
By integrating high-resolution laboratory instrumentation into the fab environment, Helios MX1 quickly reveals details that were previously only achievable in a lab. This accelerates time-to-yield by providing fast, accurate and valuable insights into semiconductor subsurface defects.

“With Helios MX1, semiconductor fab engineers can now see what was previously only visible in a laboratory,” said Mohan Iyer, semiconductor vice president and general manager at Thermo Fisher Scientific. “The semiconductor industry is witnessing a dramatic increase in the amount of analysis needed within fabrication environments, and traditional methods are no longer sufficient. With Helios MX1, our customers can now have a detailed, three-dimensional look at structures that are beneath the wafer surface.”

Thermo Fisher Scientific proudly offers the Helios MX1 to unlock the potential of fab-ready 3D process control and optimize semiconductor production. This unique solution is designed to enable semiconductor customers to improve medical devices, advance automated vehicles, enhance AI computing and more.

Learn more about the Thermo Scientific Helios MX1 PFIB-SEM on our website.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Alex Runner, Thermo Fisher Scientific
336-259-4653
alex.runner@thermofisher.com

Media Contact Information:
Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Alex Runner, Thermo Fisher Scientific
336-259-4653
alex.runner@thermofisher.com

Media Contact Information:
Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom